Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 2/20 | 0.38 |
| ▸ | CDK8 | P49336 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25284614 | 0.85 | MGLL (0.41) | MGLLCCNCCDK8KDM4E | |
| SCHEMBL29746180 | 0.83 | SLC6A3 (0.43) | CCNCCDK8NR4A2SLC6A4SLC6A3 | |
| SCHEMBL29628351 | 0.72 | ALPL (0.37) | NR4A2SLC6A4SLC6A3PDK2HPGD | |
| SCHEMBL25280246 | 0.70 | SOS1 (0.43) | NR4A2SLC6A4SLC6A3PDK2HPGD | |
| SCHEMBL30464600 | 0.70 | SOS1 (0.43) | NR4A2SLC6A4SLC6A3PDK2HPGD | |
| SCHEMBL30464605 | 0.70 | SOS1 (0.43) | NR4A2SLC6A4SLC6A3PDK2HPGD | |
| SCHEMBL29746242 | 0.69 | TSHR (0.41) | CCNCCDK8KDM4E | |
| SCHEMBL25276617 | 0.69 | PRKAG1 (0.46) | SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL31055692 | 0.69 | PRKAG1 (0.46) | SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL31055662 | 0.68 | SCN9A (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118488953-A | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023110958-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | MGLL 1/4885CCNC 2649/4885CDK8 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.